BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced that the first patient has received randomized treatment in the pivotal phase III clinical trial, exPDite-2, of …

Lilly partnership provides infrastructure to advance platform-discovered therapies targeting neurodegeneration SAN DIEGO, CA, UNITED STATES, September 22, 2025 /⁨EINPresswire.com⁩/ -- Modulo Bio, a biotechnology company developing therapies that …

Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in functional and non-motor symptoms in patients with early-stage Parkinson’s disease Solengepras was generally well-tolerated during the 12 …

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a one-shot treatment designed to replace the …

Research Triangle Park, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment of moderate-stage Parkinson’s disease in the REGENERATE-PD …

The human voice is an important health biomarker that can indicate a multitude of biological changes, including menopause, according to Yael Bensoussan, M.D., Director of the University of South Florida Health Voice Center. However, vocal changes are …

We are continuing our new series, Media Day, where we spotlight individual medical institutions and infectious disease (ID) programs. Today, we spotlight UC San Diego’s Skaggs School of Pharmacy and Pharmaceutical Sciences and the university’s extensive …

New Delhi: Bacteria from the mouth that colonize the gut may influence brain health and increase the risk of Parkinson’s disease, researchers from South Korea have found. A team at the Pohang University of Science and Technology uncovered how metabolites …

neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa Holdings, which owns the rights to market neffy in Japan …

Chinese scientists have devised "NeuroWorm", an intelligent microfiber capable of navigating freely within the body, demonstrated through lab tests on mice, providing insights for brain-machine interfaces and neural regulation in treating certain …